Cleerly LABS vs AVIEW LCS
AI Verdict
Choose Cleerly LABS if…
Choose Cleerly LABS if your primary focus is a detailed and personalized assessment of coronary artery disease, including comprehensive plaque characterization and stenosis quantification from CCTA scans. This tool is ideal for clinicians aiming to track disease progression over time and tailor heart disease management strategies based on a deep understanding of atherosclerosis.
View Cleerly LABS →Choose AVIEW LCS if…
Choose AVIEW LCS if you require an integrated solution for comprehensive cardiopulmonary assessment from a single low-dose CT scan, encompassing automated lung nodule detection, COPD analysis, and coronary artery calcification scoring. This tool is best suited for practices looking to streamline workflows and gain insights into multiple thoracic conditions simultaneously with a single scan.
View AVIEW LCS →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | Cleerly LABS | AVIEW LCS |
|---|---|---|
| Pricing | Per analysis | Contact for pricing |
| Deployment | Cloud-based (AWS), web-based application, with on-site Cleerly Proxy for data transfer. | Cloud-based, Hybrid solution, Locally on dedicated hardware, Locally virtualized (virtual machine, Docker) |
| BAA Available | Yes AI-estimated | Yes AI-estimated |
| FDA Status | Cleared AI-estimated | Cleared AI-estimated |
| HIPAA | Yes AI-estimated | Yes AI-estimated |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
AVIEW LCSAVIEW LCS offers a user-friendly viewer for both medical professionals and patients, with advanced 3D rendering and automated, detailed report generation that aids patient communication. It also emphasizes automating tedious tasks and reducing radiologist workload, streamlining the overall workflow.
Clinical Value
TieBoth tools are FDA-cleared and demonstrate strong clinical value in their specialized areas. Cleerly LABS excels in comprehensive coronary plaque characterization and non-invasive ischemia detection with prognostic utility. AVIEW LCS provides a broader 'big 3' assessment (lung cancer, COPD, and coronary artery calcification) from a single low-dose CT scan, with validated high detection rates and reduced false positives for lung nodules.
Pricing & Value
TieCleerly LABS offers transparent per-analysis pricing, providing clarity on direct costs, though the total out-of-pocket expense can be significant. AVIEW LCS, while less transparent with upfront pricing, offers flexible payment models and delivers high value through its multi-disease analysis from a single scan and documented workflow efficiencies, potentially leading to system-wide cost savings.
Enterprise Readiness
AVIEW LCSAVIEW LCS offers superior deployment flexibility, supporting cloud, hybrid, local hardware, and virtualized environments (VM, Docker), making it highly adaptable to diverse enterprise IT infrastructures. It also explicitly states seamless integration with all major PACS and minimal IT support for 'out-of-the-box installation'.
Innovation
AVIEW LCSAVIEW LCS demonstrates greater innovation by providing an integrated, fully automatic analysis for three major diseasesu2014lung cancer, COPD, and coronary artery calcificationu2014from a single low-dose CT scan. This multi-disease assessment from one imaging study represents a significant advancement in comprehensive screening and workflow efficiency.
Support & Docs
AVIEW LCSAVIEW LCS explicitly mentions the availability of 'Support documentation' and suggests a low need for IT support due to its 'out-of-the-box installation,' indicating readily available resources and ease of implementation. Cleerly LABS does not have explicit information regarding its support and documentation in the provided facts or search results.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | Cleerly LABS | AVIEW LCS |
|---|---|---|
| Product Name | Cleerly LABS | AVIEW LCS |
| Company | Cleerly | Coreline Soft Co. |
| Primary Focus | Comprehensive analysis of coronary CT angiography (CCTA) to detect, quantify, and characterize atherosclerosis and stenosis for personalized heart disease management. | Detection and analysis of lung nodules, lung cancer screening, COPD, and coronary artery calcification from a single low-dose CT scan. |
| Cardiology Analysis Features | AI-powered CCTA image analysis, comprehensive coronary plaque assessment (volume, type), stenosis detection and quantification, ischemia detection (with Cleerly ISCHEMIA module), 3D visualization of coronary arteries, personalized heart disease risk assessment, tracking disease progression over time. | Coronary Artery Calcification (CAC) scoring (Agatston, volume, mass). |
| Other Imaging Analysis Features | Not specified | Automated lung nodule detection and analysis, Lung-RADS classification and reporting, nodule volume quantification and 3D segmentation, emphysema quantification (LAA index), automated comparison of nodules in follow-up CT scans. |
| Integration Capabilities | Integration with PACS, RIS, EHR via Cleerly Proxy. | Integration with PACS/RIS and third-party platforms. |
Videos
Demos, reviews, and walkthroughs featuring Cleerly LABS and AVIEW LCS.
Frequently Asked Questions
More Comparisons
More matchups featuring Cleerly LABS or AVIEW LCS
Backers
Who funded each tool's parent company.